Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says

Executive Summary

FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients

You may also be interested in...



FDA May Revisit Accelerated Approval For Oncology Products

FDA's oncology division is interested in revisiting the accelerated approval regulations as they apply to cancer treatments

Gilead Viread Virology Data Will Distinguish HIV Drug In Physician Promotions

Gilead will highlight Viread virology data to distinguish the HIV treatment in physician promotions

HIV Trial Modified Factorial Design Best For Study In Treated Patients - Cmte.

Modified factorial trial designs are the best strategy for studying new therapies in heavily treated HIV patients, FDA's Antiviral Drugs Advisory Committee suggested.

Related Content

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel